According to the report, Medicare Part D drugs that demonstrated the lowest annual cost increases offered higher average rebates than drugs with the highest annual cost increases.
While the Trump administration is considering a proposal from HHS to overhaul safe harbor protections for rebates given by drug makers to health plans and pharmacy benefit managers as a way to bring down high drug prices, a new report prepared for America’s Health Insurance Plans (AHIP) suggests that much-maligned rebates are not to blame for increases in drug prices.
AHIP engaged consulting company Milliman to examine Medicare Part D drug prices and manufacturer rebates to help the organization prepare its comments in response to the administration’s blueprint to lower the price of drugs for American patients. Milliman used publicly available Part D drug spending and utilization data from 2013 to 2016, combined with 2016 data from contributing health plans on rebates.
According to the report, rebates are typically offered only for brand-name drugs; 81% of all of the Part D drugs analyzed offered no rebates. Furthermore, 64% of brand-name drugs did not offer rebates, and non-specialty drugs—rather than pricier specialty products—had the highest rebates when measured as a percentage of gross drug costs.
Of the 706 branded products analyzed, representing 95% of brand drug spending, only 36% had more than a nominal manufacturer rebate (rebates representing more than 1% of the drug’s gross cost), and only 27% offered significant rebates (representing 12% or more of the drug’s gross cost).
Products that face direct brand competition had a higher proportion of drugs that offered rebates (as well as a higher average rebate as a percentage of gross costs), while those in protected classes had the lowest proportion of rebates (and the lowest average rebate as a percentage of gross costs). Those products that faced direct competition offered rebates that totaled approximately 39% of gross costs, while products that were in protected classes offered rebates that totaled just 14% of the same.
Notably, while drugs with rebates offered in 2016 had higher price trends than did drugs without rebates, the average annual gross cost per Medicare beneficiary has increased more quickly for drugs that offered no rebates. Products that demonstrated the lowest annual cost increases offered higher average rebates than drugs with the highest annual cost increases.
The report’s findings suggest that addressing rebates alone will not reduce drug prices; while Milliman and AHIP’s report did not offer direct proposals as to how to address the problem of high drug prices outside of targeting rebates, competition, the findings suggest, may be the key.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.